trending Market Intelligence /marketintelligence/en/news-insights/trending/CsitGZKtqqVZD-ZCnezJ8A2 content esgSubNav
In This List

Aviragen Therapeutics to reduce staff, seeking strategic alternatives

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Aviragen Therapeutics to reduce staff, seeking strategic alternatives

Aviragen Therapeutics Inc. is reducing its head count by 25% as it explores strategic alternatives of the business, including a combination or merger.

Stifel Nicolaus & Co. Inc. will advise the company during the review process.

The company said it will not proceed with the planned phase 2 trial of Vapendavir in hematopoietic stem cell transplant patients, though it continues to evaluate a potential clinical development path for the drug.

Meanwhile, top-line efficacy data from the phase 2 trial evaluating BTA074 to treat condyloma caused by human papillomavirus is expected in the first half of 2018.